A phase 3 trial of Scholar Rock’s spinal muscular atrophy (SMA) candidate has hit its primary endpoint, sparking a 200%-plus premarket surge in the biotech’s stock price. Investors went wild despite the higher dose falling short of the targeted efficacy and Scholar Rock making no mention of a key secondary goal. Read more below: https://lnkd.in/eb7uUbGh #clinicaltrials #pharmastock #stockprices
Mantell Associates
Executive Search Services
City of London, England 93,643 followers
Multidiscipline Global Life Science and Pharmaceutical Headhunting Firm.
About us
Mantell Associates is a multi-discipline headhunting firm focused on providing both permanent and contract recruitment services globally, to the Biotech, Pharmaceutical, CDMO, CRO, Diagnostics, Animal Health, Consulting, Medical Device and MedTech sectors. With success ranging across C-Suite, Commercial, Technical Operations, Scientific, Clinical, Quality and Regulatory, we pride ourselves on our ability to bring the top talent to our clients, and the best opportunities to the top talent. Our services span across our Partnership Service, Contingency, Project Management and Contract models, meaning that we can cater to our client’s every requirement.
- Website
-
www.mantellassociates.com
External link for Mantell Associates
- Industry
- Executive Search Services
- Company size
- 51-200 employees
- Headquarters
- City of London, England
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Contract Development Manufacturing Organisations, Contract Manufacturing Organisations, Preclinical, Active Pharmaceutical Ingredients, Cell & Gene Therapy, Finished Dosage Forms, Biologics, Toxicology, Pharmacology, Oncology, CDMO, CMO, Biomarkers, Vaccines, Contract Research Organisation, Clinical Trial Supplies, Bioanalytics, Bioanalysis, Fine Chemicals, and Highly Potent Active Pharmaceutical Ingredients
Locations
-
Primary
150 Minories
City of London, England EC3N 1LS, GB
-
2 S Biscayne Blvd
Miami, Florida 33131, US
-
Rigistrasse 3
Zug, 6300, CH
Employees at Mantell Associates
Updates
-
New opportunity! Process Engineer - Contract - USA. Mantell Associates are currently partnered with an innovative Engineering company who are searching for a Process Engineer (Visual Inspection). As Process Engineer, you will function as an integral part of the creation of packaging operations at client’s first manufacturing facility. Apply for this role online - https://lnkd.in/exXm8J6D - or contact Robin Mantell on +1 (786) 485 1298. #processengineer #engineerjobs #engineeringjobs
-
In today’s competitive and fast-evolving pharmaceutical recruitment market, the importance of client relationships cannot be overstated. Dontye Carriere discusses how the true differentiator is often the strength of the relationships a recruitment firm builds with its clients. These relationships not only fuel repeat business but also create a foundation for long-term stability and growth in an industry marked by both highs and lows, which has always been a key focus for Mantell Associates. Read more below: https://lnkd.in/enXQn6DW #pharmarecruitment #clientrelationships #recruitmenttips
The Importance of Client Relationships in Pharma Recruitment
https://www.mantellassociates.com
-
Sterling Pharma Solutions and Soligenix, Inc. entered an agreement for Sterling to manufacture a GMP-quality synthetic hypericin developed by Soligenix, for its oncology drug, HyBryte, for clinical trials. Read more below: https://lnkd.in/evZDjigx #gmp #oncology #oncologynews
Sterling Pharma, Soligenix Partner to Manufacture Oncology API
contractpharma.com
-
Today is World Mental Health Day, and this year's theme from the Mental Health Foundation is 'it is time to prioritise mental health in the workplace'. With this in mind, our team enjoyed a late start, team breakfast and will also finish early! These are just small things to show appreciation for our team who work incredibly hard day in, day out. #mentalhealthday #worldmentalhealthday #workplacementalhealth
-
Recipharm is expanding its pharmaceutical development capabilities, through investments and the integration of cutting-edge technologies. This investment aims to enhance services for early- and late- stage product development, including clinical study supply at small and pilot scales and wide range of commercial technologies. Read more below: https://lnkd.in/eBNmcG45 #cdmo #osd #pharmanews
Recipharm Expands Pharmaceutical Development Capabilities
contractpharma.com
-
Ferring Pharmaceuticals has opened a new global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin. This represents a significant milestone in Ferring’s capabilities and capacity to meet the growth in demand for this gene therapy for people with non-muscle invasive bladder cancer (NMIBC). Read more below: https://lnkd.in/eEXEeFbx #manufacturing #pharmamanufacturing #genetherapy
Ferring Pharmaceuticals Opens New Manufacturing Site in Finland
contractpharma.com
-
Huge congratulations to Jay Lefley who has been promoted to Managing Associate! Jay joined the MA team back in October 2023, and since then has built a strong network within the Clinical and R&D sector across Europe, APAC and the USA. He is a valued member of our Contract division, and will grow his team in his new role as Managing Associate. Congratulations Jay - well deserved and we look forward to your continued success! #promotion #recruitment #recruitmentlondon
-
Recordati has entered an agreement with Sanofi to acquire the global rights to Enjaymo (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder. Read more below: https://lnkd.in/e5VYGUb7 #antibodies #biologics #acquisition
Recordati to Acquire Sanofi's Enjaymo for $825M Upfront
contractpharma.com
-
Respiratory medicine is one frontier of the global healthcare landscape which has undergone significant transformations in recent years. AstraZeneca, a longstanding pioneer of innovation in this field, continues to push boundaries and redefine patient care. In this enlightening interview, Fierce Pharma sits down with Prof. Maria Belvisi, SVP and Head of Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D at AstraZeneca. Belvisi offers unique insights into the company's ambitious goals and scientific strategies in respiratory research. Read more below: https://lnkd.in/ekGyKsGT #respiratorymedicine #healthcare #scientificnews
AstraZeneca's vision for the future of respiratory care
fiercepharma.com